Literature DB >> 22299394

The anti-arrhythmic effects of prednisone in patients with sarcoidosis.

Amr Mohsen1.   

Abstract

Atrial fibrillation (AF) affects 2.3 million people in the United States and is currently the most common cardiac arrhythmia. Its overall prevalence is only increasing as the population ages. The classical risk factors for developing AF include hypertension, valvular disease, ischemic cardiomyopathy, and thyroid disease. In some patients with AF, an underlying cardiovascular pathology is not identified and the etiology remains unknown. Treatment modalities for AF typically include rate control medications, antiarrhythmics and radio frequency ablation (RFA), each of which is accompanied by its own risk of complications. We report a case of symptomatic AF that was refractory to multiple antiarrhythmics and an RFA procedure which resolved with prednisone. In this case, AF was associated with cardiac sarcoidosis, a disorder that is thought to be due to granulomatous involvement of the myocardium and increased systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22299394     DOI: 10.1080/ac.66.6.2136967

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  2 in total

Review 1.  Atrial Fibrillation in Cardiac Sarcoidosis.

Authors:  Davendra Mehta; Jonathan M Willner; Philippe R Akhrass
Journal:  J Atr Fibrillation       Date:  2015-12-31

2.  Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes.

Authors:  Willy Weng; Christiane Wiefels; Santabhanu Chakrabarti; Pablo B Nery; Emel Celiker-Guler; Jeff S Healey; Tomasz W Hruczkowski; F Russell Quinn; Steven Promislow; Maria C Medor; Stewart Spence; Roupen Odabashian; Wael Alqarawi; Daniel Juneau; Rob de Kemp; Eugene Leung; Rob Beanlands; David Birnie
Journal:  J Am Heart Assoc       Date:  2020-08-20       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.